AmpliPhi Biosciences Corp. (APHB)

1.22
0.05 4.30
AMEX : Health Technology
Prev Close 1.17
Open 1.25
Day Low/High 1.20 / 1.25
52 Wk Low/High 0.67 / 2.05
Volume 212.56K
Avg Volume 293.70K
Exchange AMEX
Shares Outstanding 16.46M
Market Cap 19.49M
EPS -2.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

AmpliPhi Biosciences Announces Presentation Of Bacteriophage Therapy Case Study At ISHLT Annual Meeting

AmpliPhi Biosciences Announces Presentation Of Bacteriophage Therapy Case Study At ISHLT Annual Meeting

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the presentation...

AmpliPhi Biosciences Announces Closing Of Registered Direct Offering Of Common Stock

AmpliPhi Biosciences Announces Closing Of Registered Direct Offering Of Common Stock

AmpliPhi Biosciences Corporation (NYSE American: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced the closing of its previously...

AmpliPhi Biosciences Announces Registered Direct Offering Of Common Stock

AmpliPhi Biosciences Announces Registered Direct Offering Of Common Stock

AmpliPhi Biosciences Corporation (NYSE American: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has entered into...

AmpliPhi To Collaborate With Western Sydney Local Health District And Westmead Institute For Medical Research On Expanded Access For Investigational Bacteriophage Therapeutics AB-SA01 And AB-PA01

AmpliPhi To Collaborate With Western Sydney Local Health District And Westmead Institute For Medical Research On Expanded Access For Investigational Bacteriophage Therapeutics AB-SA01 And AB-PA01

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced a collaboration...

AmpliPhi Biosciences Reports Fourth Quarter And Full Year 2017 Financial Results And Business Highlights

AmpliPhi Biosciences Reports Fourth Quarter And Full Year 2017 Financial Results And Business Highlights

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced financial results...

AmpliPhi To Collaborate With The U.S. Department Of Veterans Affairs On Expanded Access For Investigational Bacteriophage Therapeutics AB-SA01 And AB-PA01

AmpliPhi To Collaborate With The U.S. Department Of Veterans Affairs On Expanded Access For Investigational Bacteriophage Therapeutics AB-SA01 And AB-PA01

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced a Cooperative...

AmpliPhi Biosciences Announces Presentation Of Preclinical Data Demonstrating That AB-PA01 Reduces Biofilm In Pseudomonas Aeruginosa In Vivo Model

AmpliPhi Biosciences Announces Presentation Of Preclinical Data Demonstrating That AB-PA01 Reduces Biofilm In Pseudomonas Aeruginosa In Vivo Model

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the presentation...

AmpliPhi Biosciences Announces Pricing Of $4.0 Million Public Offering Of Common Stock

AmpliPhi Biosciences Announces Pricing Of $4.0 Million Public Offering Of Common Stock

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the pricing of a...

AmpliPhi Biosciences Announces Proposed Public Offering Of Common Stock

AmpliPhi Biosciences Announces Proposed Public Offering Of Common Stock

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it intends...

AmpliPhi Biosciences Announces Positive Interim Results For Single-Patient Expanded Access Program Utilizing AB-SA01 And AB-PA01

AmpliPhi Biosciences Announces Positive Interim Results For Single-Patient Expanded Access Program Utilizing AB-SA01 And AB-PA01

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced topline results...

AmpliPhi Biosciences To Present At Biotech Showcase 2018

AmpliPhi Biosciences To Present At Biotech Showcase 2018

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced...

AmpliPhi Biosciences Provides Corporate And Strategic Update

AmpliPhi Biosciences Provides Corporate And Strategic Update

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced its...

AmpliPhi Biosciences To Present At LD Micro 10th Annual Main Event

AmpliPhi Biosciences To Present At LD Micro 10th Annual Main Event

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced...

AmpliPhi Biosciences Reports Third Quarter 2017 Financial Results And Business Highlights

AmpliPhi Biosciences Reports Third Quarter 2017 Financial Results And Business Highlights

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced...

AmpliPhi Biosciences To Hold 2017 Third Quarter And Business Update Conference Call On November 14

AmpliPhi Biosciences To Hold 2017 Third Quarter And Business Update Conference Call On November 14

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced...

AmpliPhi Biosciences To Participate In The BIO-Europe 2017 Conference

AmpliPhi Biosciences To Participate In The BIO-Europe 2017 Conference

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced...

AmpliPhi Biosciences To Participate In Two Upcoming Conferences

AmpliPhi Biosciences To Participate In Two Upcoming Conferences

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced...

AmpliPhi Biosciences Announces Publication Of Preclinical Data For AB-PA01 Showing Activity In Reducing Biofilms Of Pseudomonas Aeruginosa

AmpliPhi Biosciences Announces Publication Of Preclinical Data For AB-PA01 Showing Activity In Reducing Biofilms Of Pseudomonas Aeruginosa

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced the...

AmpliPhi Biosciences' CEO To Moderate Panel Discussion At Upcoming Anti-Infectives Rx Conference

AmpliPhi Biosciences' CEO To Moderate Panel Discussion At Upcoming Anti-Infectives Rx Conference

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces that CEO...

AmpliPhi Biosciences Announces First Intravenous Treatment Of A Patient With AB-SA01 Targeting Staphylococcus Aureus

AmpliPhi Biosciences Announces First Intravenous Treatment Of A Patient With AB-SA01 Targeting Staphylococcus Aureus

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces the...

AmpliPhi Biosciences Announces Receipt Of $2.0 Million R&D Tax Incentive

AmpliPhi Biosciences Announces Receipt Of $2.0 Million R&D Tax Incentive

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces that it...

AmpliPhi Biosciences To Present At Rodman & Renshaw 19th Annual Global Investment Conference

AmpliPhi Biosciences To Present At Rodman & Renshaw 19th Annual Global Investment Conference

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces that Paul...

AmpliPhi Biosciences Announces Publication Of Bacteriophage Case Study For Life-Threatening Antibiotic-Resistant Infection

AmpliPhi Biosciences Announces Publication Of Bacteriophage Case Study For Life-Threatening Antibiotic-Resistant Infection

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces publication of...

AmpliPhi Biosciences Reports Second Quarter 2017 Financial Results And Business Highlights

AmpliPhi Biosciences Reports Second Quarter 2017 Financial Results And Business Highlights

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a leader in the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces financial results for the three and six months ended...

AmpliPhi Biosciences To Hold 2017 Second Quarter And Business Update Conference Call On August 14

AmpliPhi Biosciences To Hold 2017 Second Quarter And Business Update Conference Call On August 14

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces that management will hold a business...

AmpliPhi Biosciences To Present At Bacteriophage Therapy Workshop Sponsored By The FDA And NIH

AmpliPhi Biosciences To Present At Bacteriophage Therapy Workshop Sponsored By The FDA And NIH

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces that it has been invited to...

TheStreet Quant Rating: E+ (Sell)